NBIX - Neurocrine says new Ingrezza version is under FDA review
2023-09-14 08:54:47 ET
More on Neurocrine
- Seeking Alpha’s Quant Rating on Neurocrine Biosciences
- Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It
- Neurocrine Biosciences: Ingrezza Impresses Amid Costly Pipeline Expansion Efforts
- Neurocrine Biosciences, Inc. ( NBIX ) Q2 2023 Earnings Call Transcript
- Neurocrine gains after Phase 3 win for genetic disorder drug
- Neurocrine releases new data on Ingrezza for Huntington's disease chorea
- Neurocrine nabs FDA label expansion for Ingrezza
For further details see:
Neurocrine says new Ingrezza version is under FDA review